KRAS Activating Mutation clinical trials at UCSF

1 research study open to eligible people

KRAS activating mutation causes cancer. UCSF is recruiting for a clinical trial for people with G12C Non-Small Cell Lung Cancer. The trial is testing the medications avutometinib and adagrasib together for those who have had previous G12C treatment.

Showing trials for

  • Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

    open to eligible people ages 18 years and up

    This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.

    San Francisco, California and other locations

Our lead scientists for KRAS Activating Mutation research studies include .

Last updated: